Cellulose acetate dialyzer expiration dating may be required; FDA issues alert following patient injuries.
This article was originally published in The Gray Sheet
Executive Summary
CELLULOSE ACETATE DIALYZER EXPIRATION DATING REQUIREMENT likely will be developed by FDA in response to recent adverse events with the devices. The events, all occurring in September at a Huntsville, Alabama hospital, are thought to be related to use of 10-year-old cellulose acetate dialyzers to treat seven patients who developed conjunctivitis, visual loss, and/or hearing loss within 24 hours of hemodialysis.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.